For payers and employers managing musculoskeletal costs, the question has never been whether MSK spend is a problem – it’s whether there’s a proven solution. To find out, Airrosti engaged Optum Advisory, one of the most respected names in healthcare analytics, to independently examine whether Airrosti patients generate meaningfully different cost outcomes than patients treated by other MSK providers. Here’s what they found:
Airrosti patients generated $3,607 less in total healthcare costs per member per year than a matched control group of comparable patients treated by other MSK providers
Airrosti patients avoided more surgeries, fewer ER visits, and less downstream care, reflecting a fundamentally different and more effective care pathway
The largest savings came from outpatient surgery ($1,041 PMPY) and professional services ($925 PMPY), two of the highest-cost categories payers and employers are most focused on reducing
Significant cost savings held even under conservative definitions of MSK spend, with $2,329 PMPY in savings when limited to musculoskeletal-specific claims only
Results were statistically significant with a p-value of less than 0.0001, independently validated by Optum using propensity score matching across real claims data
This is the most rigorous, independently validated evidence Airrosti has produced to date, and a compelling case for how smarter MSK benefit design can drive real, measurable financial impact. Reach out to us to learn more.
© Copyrights Airrosti Rehab Center, LLC 2024. All rights reserved. | Privacy Policy | Standards & Practices | Terms of Use & Service | HIPAA Notice of Privacy Practices | Disclaimer | Equal Opportunity Employer | Notice of Non-Discrimination
“Airrosti” is the registered tradename used for Airrosti Rehab Centers, LLC and its various subsidiary and affiliated entities, which provide musculoskeletal treatment services. Airrosti providers are doctors of chiropractic or doctors of physical therapy.
